Epigenetic down regulation of RASSF10 and its possible clinical implication in prostate carcinoma

Prostate

Volumn 72, Issue 14, 2012, Pages 1550-1558

  Dansranjavin, Temuujin ^a   Wagenlehner, Florian ^a   Gattenloehner, Stefan ^a   Steger, Klaus ^a   Weidner, Wolfgang ^a   Dammann, Reinhard ^a   Schagdarsurengin, Undraga ^a  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

Author keywords

epigenetic inactivation; prostate carcinoma; RASSF10

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; MESSENGER RNA; PROTEIN RAS ASSOCIATION DOMAIN FAMILY 10; RAS PROTEIN; TRICHOSTATIN A; UNCLASSIFIED DRUG;

ADULT; AGED; APOPTOSIS; ARTICLE; BIOASSAY; CANCER CELL CULTURE; CANCER STAGING; CARCINOGENESIS; CARCINOMA CELL; COLONY FORMATION; CONTROLLED STUDY; DEMETHYLATION; DOWN REGULATION; EPIGENETICS; GENE EXPRESSION; HISTOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; METHYLATION; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE; PROSTATE CARCINOMA; PROSTATE HYPERTROPHY; PROSTATECTOMY; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PYROSEQUENCING; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

AGED; CELL LINE, TUMOR; DNA METHYLATION; DOWN-REGULATION; EPIGENOMICS; FLOW CYTOMETRY; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, NEOPLASM; ROC CURVE; SEQUENCE ANALYSIS, DNA; STATISTICS, NONPARAMETRIC; TUMOR SUPPRESSOR PROTEINS;

EID: 84865488157     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.22510     Document Type: Article

References (22)

1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ,. Cancer statistics, 2005. CA Cancer J Clin 2005; 55: 10-30;. (Pubitemid 40310185)
2. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F,. EAU guidelines on prostate cancer. Part 1: Screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011; 59: 61-71;.
3. Dammann R, Li C, Yoon JH, Chin PL, Bates S, Pfeifer GP,. Epigenetic inactivation of a RAS association domain family protein from the lung tumour suppressor locus 3p21.3. Nat Genet 2000; 25: 315-319;. (Pubitemid 30437320)
4. Richter AM, Pfeifer GP, Dammann RH,. The RASSF proteins in cancer; from epigenetic silencing to functional characterization. Biochim Biophys Acta 2009; 1796: 114-128;.
5. Pelosi G, Fumagalli C, Trubia M, Sonzogni A, Rekhtman N, Maisonneuve P, Galetta D, Spaggiari L, Veronesi G, Scarpa A, Malpeli G, Viale G,. Dual role of RASSF1 as a tumor suppressor and an oncogene in neuroendocrine tumors of the lung. Anticancer Res 2010; 30: 4269-4281;.
6. Lee CK, Lee JH, Lee MG, Jeong SI, Ha TK, Kang MJ, Ryu BK, Hwangbo Y, Shim JJ, Jang JY, Lee KY, Kim HJ, Chi SG,. Epigenetic inactivation of the NORE1 gene correlates with malignant progression of colorectal tumors. BMC Cancer 2010; 10: 577.
7. Schagdarsurengin U, Richter AM, Hornung J, Lange C, Steinmann K, Dammann RH,. Frequent epigenetic inactivation of RASSF2 in thyroid cancer and functional consequences. Mol Cancer 2010; 9: 264-276;.
8. Donninger H, Hesson L, Vos M, Beebe K, Gordon L, Sidransky D, Liu JW, Schlegel T, Payne S, Hartmann A, Latif F, Clark GJ,. The Ras effector RASSF2 controls the PAR-4 tumor suppressor. Mol Cell Biol 2010; 30: 2608-2620;.
9. Sherwood V, Recino A, Jeffries A, Ward A, Chalmers AD,. The N-terminal RASSF family: A new group of Ras-association-domain-containing proteins, with emerging links to cancer formation. Biochem J 2009; 425: 303-311;.
10. Sherwood V, Manbodh R, Sheppard C, Chalmers AD,. RASSF7 is a member of a new family of RAS association domain-containing proteins and is required for completing mitosis. Mol Biol Cell 2008; 19: 1772-1782;. (Pubitemid 351805128)
11. Hesson LB, Dunwell TL, Cooper WN, Catchpoole D, Brini AT, Chiaramonte R, Griffiths M, Chalmers AD, Maher ER, Latif F,. The novel RASSF6 and RASSF10 candidate tumour suppressor genes are frequently epigenetically inactivated in childhood leukaemias. Mol Cancer 2009; 8: 42-52;.
12. Hill VK, Underhill-Day N, Krex D, Robel K, Sangan CB, Summersgill HR, Morris M, Gentle D, Chalmers AD, Maher ER, Latif F,. Epigenetic inactivation of the RASSF10 candidate tumor suppressor gene is a frequent and an early event in gliomagenesis. Oncogene 2011; 8: 978-989;.
13. Schagdarsurengin U, Richter AM, Wohler C, Dammann RH,. Frequent epigenetic inactivation of RASSF10 in thyroid cancer. Epigenetics 2009; 4: 571-576;.
14. Ries LAG, Melbert D, Krapcho M,. SEER Cancer Statistics Review, 1975-2005. Natl Cancer Inst 2008; CSR 1975-2005:14.
15. Steger K, Klonisch T, Gavenis K, Drabent B, Doenecke D, Bergmann M,. Expression of mRNA and protein of nucleoproteins during human spermiogenesis. Mol Hum Reprod 1998; 4: 939-945;. (Pubitemid 28475248)
16. Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, Henrique R, Nelson WG, Shariat SF,. Epigenetics in prostate cancer: Biologic and clinical relevance. Eur Urol 2011; 60: 753-766;.
17. Zhu W, Qin W, Hewett JE, Sauter ER,. Quantitative evaluation of DNA methylation in malignant and benign breast tissue and fluids. Int J Cancer 2010; 126: 474-482;.
18. Delgado-Cruzata L, Hruby GW, Gonzalez K, McKiernan J, Benson MC, Santella RM, Shen J,. DNA methylation changes correlate with Gleason score and tumor stage in prostate cancer. DNA Cell Biol 2012; 31 (2): 187-192;.
19. Dahiya R, McCarville J, Lee C, Hu W, Kaur G, Carroll P, Deng G,. Deletion of chromosome 11p15, p12, q22, q23-24 loci in human prostate cancer. Int J Cancer 1997; 72 (2): 283-288;. (Pubitemid 27314886)
20. Recino A, Sherwood V, Flaxman A, Cooper WN, Latif F, Ward A, Chalmers AD,. Human RASSF7 regulates the microtubule cytoskeleton and is required for spindle formation, Aurora B activation and chromosomal congression during mitosis. Biochem J 2010; 430: 207-213;.
21. Falvella FS, Manenti G, Spinola M, Pignatiello C, Conti B, Pastorino U, Dragani TA,. Identification of RASSF8 as a candidate lung tumor suppressor gene. Oncogene 2006; 25: 3934-3938;. (Pubitemid 43990748)
22. Lock FE, Underhill-Day N, Dunwell T, Matallanas D, Cooper W, Hesson L, Recino A, Ward A, Pavlova T, Zabarovsky E, Grant MM, Maher ER, Chalmers AD, Kolch W, Latif F,. The RASSF8 candidate tumor suppressor inhibits cell growth and regulates the Wnt and NF-kappaB signaling pathways. Oncogene 2010; 29: 4307-4316;.